Rikisha Gupta

Rikisha Gupta

Auto-generated profile, based on publicly available information

Rikisha Gupta

National Heart and Lung Institute, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2023 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
RGRikisha Shah Gupta
Rikisha Shah Gupta
AKArdita Koteci
Ardita Koteci
AMAnn Morgan
Ann Morgan
PGPeter M George
Peter M George
JQJennifer K Quint
Jennifer K Quint
Interstitial lung disease (ILD) is a collective term representing a diverse group of pulmonary fibrotic and inflammatory conditions. Due to the diversity of ILD conditions, paucity of guidance and updates to diagnostic criteria over time, it has been challenging to precisely determine ILD incidence and prevalence. This systematic review provides a synthesis of published data at a global level and highlights gaps in the current knowledge base. Medline and Embase databases were searched systematically for studies reporting incidence and prevalence of various ILDs. Randomised controlled trials, case reports and conference abstracts were excluded. 80 studies were included, the most described subgroup was autoimmune-related ILD, and the most studied conditions were rheumatoid arthritis (RA)-associated ILD, systemic sclerosis associated (SSc) ILD and idiopathic pulmonary fibrosis (IPF). The prevalence of IPF was mostly established using healthcare datasets, whereas the prevalence of autoimmune ILD tended to be reported in smaller autoimmune cohorts. The prevalence of IPF ranged from 7 to 1650 per 100 000 persons. Prevalence of SSc ILD and RA ILD ranged from 26.1% to 88.1% and 0.6% to 63.7%, respectively. Significant heterogeneity was observed in the reported incidence of various ILD subtypes. This review demonstrates the challenges in establishing trends over time across regions and highlights a need to standardise ILD diagnostic criteria.PROSPERO registration number: CRD42020203035.

29 December 2021 in BMJ
Verified
Journal Article
Open access
PDF file
HWHannah R Whittaker
Hannah R Whittaker
CGClaudia Gulea
Claudia Gulea
AKArdita Koteci
Ardita Koteci
CKConstantinos Kallis
Constantinos Kallis
AMAnn D Morgan
Ann D Morgan
JQJennifer Kathleen Quint
Jennifer Kathleen Quint
Objectives To describe the rates for consulting a general practitioner (GP) for sequelae after acute covid-19 in patients admitted to hospital with covid-19 and those managed in the community, and to determine how the rates change over time for patients in the community and after vaccination for covid-19. Design Population based study. Setting 1392 general practices in England contributing to the Clinical Practice Research Datalink Aurum database. Participants 456 002 patients with a diagnosis of covid-19 between 1 August 2020 and 14 February 2021 (44.7% men; median age 61 years), admitted to hospital within two weeks of diagnosis or managed in the community, and followed-up for a maximum of 9.2 months. A negative control group included individuals without covid-19 (n=38 511) and patients with influenza before the pandemic (n=21 803). Main outcome measures Comparison of rates for consulting a GP for new symptoms, diseases, prescriptions, and healthcare use in individuals admitted to hospital and those managed in the community, separately, before and after covid-19 infection, using Cox regression and negative binomial regression for healthcare use. The analysis was repeated for the negative control and influenza cohorts. In individuals in the community, outcomes were also described over time after a diagnosis of covid-19, and compared before and after vaccination for individuals who were symptomatic after covid-19 infection, using negative binomial regression. Results Relative to the negative control and influenza cohorts, patients in the community (n=437 943) had significantly higher GP consultation rates for multiple sequelae, and the most common were loss of smell or taste, or both (adjusted hazard ratio 5.28, 95% confidence interval 3.89 to 7.17, P<0.001); venous thromboembolism (3.35, 2.87 to 3.91, P<0.001); lung fibrosis (2.41, 1.37 to 4.25, P=0.002), and muscle pain (1.89, 1.63 to 2.20, P<0.001); and also for healthcare use after a diagnosis of covid-19 compared with 12 months before infection. For absolute proportions, the most common outcomes ≥4 weeks after a covid-19 diagnosis in patients in the community were joint pain (2.5%), anxiety (1.2%), and prescriptions for non-steroidal anti-inflammatory drugs (1.2%). Patients admitted to hospital (n=18 059) also had significantly higher GP consultation rates for multiple sequelae, most commonly for venous thromboembolism (16.21, 11.28 to 23.31, P<0.001), nausea (4.64, 2.24 to 9.21, P<0.001), prescriptions for paracetamol (3.68, 2.86 to 4.74, P<0.001), renal failure (3.42, 2.67 to 4.38, P<0.001), and healthcare use after a covid-19 diagnosis compared with 12 months before infection. For absolute proportions, the most common outcomes ≥4 weeks after a covid-19 diagnosis in patients admitted to hospital were venous thromboembolism (3.5%), joint pain (2.7%), and breathlessness (2.8%). In patients in the community, anxiety and depression, abdominal pain, diarrhoea, general pain, nausea, chest tightness, and tinnitus persisted throughout follow-up. GP consultation rates were reduced for all symptoms, prescriptions, and healthcare use, except for neuropathic pain, cognitive impairment, strong opiates, and paracetamol use in patients in the community after the first vaccination dose for covid-19 relative to before vaccination. GP consultation rates were also reduced for ischaemic heart disease, asthma, and gastro-oesophageal disease. Conclusions GP consultation rates for sequelae after acute covid-19 infection differed between patients with covid-19 who were admitted to hospital and those managed in the community. For individuals in the community, rates of some sequelae decreased over time but those for others, such as anxiety and depression, persisted. Rates of some outcomes decreased after vaccination in this group.

30 April 2024 in Thorax
Verified
Journal Article
Closed access
PDF file
RGRikisha Gupta
Rikisha Gupta
AMAnn Dorothy Morgan
Ann Dorothy Morgan
PGPeter M George
Peter M George
JQJennifer Kathleen Quint
Jennifer Kathleen Quint
Background Owing to discrepancies in methodologies and how idiopathic pulmonary fibrosis (IPF) is diagnosed it is challenging to establish a consistent understanding of the disease burden In the UK, over 10 years ago, the incidence and prevalence of IPF were reported as 2.8–8.7 per 100 000 person-years (from 2000 to 2012) and 39 per 100 000 persons (in 2012), respectively. Here, we estimated the incidence and prevalence of IPF in England from 2008 to 2018 and investigated IPF mortality. Methods Using Clinical Practice Research Datalink Aurum and Hospital Episode Statistics (HES) linked datasets, we estimated incidence and prevalence using four validated diagnostic-code-based algorithms. Using the registered number of deaths (from Office of National Statistics) with the underlying cause being recorded as IPF, we estimated IPF mortality for the same period. Results Using Aurum-based definitions, incidence increased over time by 100% for Aurum narrow (3–6.1 per 100 000 person-years) and by 25% for Aurum broad (22.4–28.6 per 100 000 person-years). However, using HES-based definitions showed a decrease in incidence over the same period and lay between the two extremes derived for Aurum-based definition. IPF mortality in 2018 was 7.9 per 100 000 person-years and increased by 53% between 2008 and 2018. Interpretation When using best-case definitions, incidence rose throughout the study period. Scaling this to England’s population (2018), our best estimate would be in the range of 8000–9000 new cases per year which is higher than previously reported estimates (5000–6000). This increased burden in the new cases of IPF each year impacts future health service planning and resource allocation.

13 April 2021 in medRxiv
Verified
Preprint
Open access
PDF file
HWHannah R Whittaker
Hannah R Whittaker
CGClaudia Gulea
Claudia Gulea
AKArdita Koteci
Ardita Koteci
CKConstantinos Kallis
Constantinos Kallis
AMAnn D Morgan
Ann D Morgan
JQJennifer Kathleen Quint
Jennifer Kathleen Quint
Objective: To compare post-COVID-19 sequelae between hospitalised and non-hospitalised individuals Design: Population-based cohort study Setting: 1,383 general practices in England contributing to Clinical Practice Research Database Aurum Participants: 46,687 COVID-19 cases diagnosed between 1 st August to 17 th October 2020 (45.4% male; mean age 40), either hospitalised within two weeks of diagnosis or non-hospitalised, and followed-up for a maximum of three months. Main outcome measures: Event rates of new symptoms, diseases, prescriptions and healthcare utilisation in hospitalised and non-hospitalised individuals, with between-group comparison using Cox regression. Outcomes compared at 6 and 12 months prior to index date, equating to first UK wave and pre-pandemic. Non-hospitalised group outcomes stratified by age and sex. Results: 45,272 of 46,687 people were non-hospitalised; 1,415 hospitalised. Hospitalised patients had higher rates of 13/26 symptoms and 11/19 diseases post-COVID-19 than the community group, received more prescriptions and utilised more healthcare. The largest differences were noted for rates per 100,000 person-weeks [95%CI] of breathlessness: 536 [432 to 663] v. 85 [77 to 93]; joint pain: 295 [221 to 392] v. 168 [158 to 179]; diabetes: 303 [225 to 416] v. 36 [32 to 42], hypertension: 244 [178 to 344] v. 47 [41 to 53]. Although low, rates of chest tightness, tinnitus and lung fibrosis were higher in the community group. 4.2% (1882/45,272) of the community group had a post-acute burden, most frequently reporting anxiety, breathlessness, chest pain and fatigue. In those non-hospitalised, age and sex differences existed in outcome rates. Healthcare utilisation in the community group increased 28.5% post-COVID-19 relative to pre-pandemic. Conclusions: Post-COVID-19 sequelae differ between hospitalised and non-hospitalised individuals, with age and sex-specific differences in those non-hospitalised. Most COVID-19 cases managed in the community do not report ongoing issues to healthcare professionals. Post-COVID-19 follow-up and management strategies need to be tailored to specific groups.

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
RGRikisha Gupta
Rikisha Gupta
VSValentina Shvachko
Valentina Shvachko
ALAmos Lichtman
Amos Lichtman
MBMark Berry
Mark Berry
FSFlorentin Scarlat
Florentin Scarlat
ACAnand Chokkalingam
Anand Chokkalingam
As the pandemic has evolved, those with COVID-19 have exhibited less severe disease, with decreased overall mortality and an increase in the proportion of individuals diagnosed in the community. However, there is a lack of data on the clinical characteristics and outcomes for nonhospitalized individuals. This descriptive analysis summarizes the demographics, clinical characteristics, and outcomes of high-risk patients diagnosed with COVID-19 in an outpatient (OP) setting. This retrospective cohort analysis used the HealthVerity database, which includes medical and pharmacy claims (commercial, Medicare, and Medicaid plans) from >330 million patients within the United States. Participants were aged ≥18 years and diagnosed with COVID-19 as OPs (study period: March 1, 2020 to November 30, 2022). Patients were followed from the index date (date of COVID-19 diagnosis) to the earliest of the following: 3 months post-index, in-hospital death, end of study period, or end of follow-up). Patients were characterized by the presence of risk factors for disease progression (RFs) at baseline and the reporting of specific COVID-19 related symptoms. COVID-19-related hospitalization and all-cause hospitalization were the evaluated outcomes. Prevalence of Risk Factors for COVID-19 Progression in Those Diagnosed with COVID-19 in an Outpatient Setting COPD, chronic obstructive pulmonary disease. COVID-19-related Hospitalization and All-cause Hospitalization Within 28 Days of Index Date in Patients Diagnosed with COVID-19 in an Outpatient Setting, Stratified by the Number of Risk Factors Most patients diagnosed with COVID-19 in an OP setting had ≥1 RF; an increase in the presence of RFs was associated with an increased risk of hospitalization. The availability of safe and well-tolerated COVID-19 therapeutics could prevent disease progression and decrease the rate of hospitalization in vulnerable populations. Rikisha Gupta, MPH, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Valentina Shvachko, MS, Gilead Sciences, Inc: Employee|Gilead Sciences, Inc: Stocks/Bonds Amos Lichtman, MPH, MD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Mark Berry, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Florentin Scarlat, MA, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Anand Chokkalingam, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds